We tested in vitro the activities of streptomycin and tetracycline-antibiotics that have long been used to treat rhinoscleroma-as well as several newer oral agents by using 23 isolates of the causative organism KlebsieUla rhinosckeromatis. All isolates were inhibited by clinically achievable concentrations of trimethoprim-sulfamethoxazole, amoxicillin-clavulanate, chloramphenicol, ciprofloxacin, cephalexin, cefuroxime, and cefpodoxime.
We tested in vitro the activities of streptomycin and tetracycline-antibiotics that have long been used to treat rhinoscleroma-as well as several newer oral agents by using 23 isolates of the causative organism KlebsieUla rhinosckeromatis. All isolates were inhibited by clinically achievable concentrations of trimethoprim-sulfamethoxazole, amoxicillin-clavulanate, chloramphenicol, ciprofloxacin, cephalexin, cefuroxime, and cefpodoxime.
Klebsiella rhinoscleromatis causes rhinoscleroma, a chronic granulomatous infection of the upper airways. This disease occurs sporadically in the United States (3, 11, 19) ; but it is endemic in parts of Europe, Africa, Central and South America, and southern Asia, where thousands of humans may be afflicted (12) . Prolonged antimicrobial treatment is required to cure rhinoscleroma. Streptomycin in combination with tetracycline has long been regarded as the standard treatment (7, 10) , although rifampin (7, 8) has more recently been found to be effective either by topical application or oral ingestion. Trimethoprim-sulfamethoxazole (TMP-SMX) (1, 7) has also been recommended, but this recommendation has been made in the absence of published clinical trials. Anecdotal reports describe the efficacy of expanded-spectrum cephalosporins (3) . No systematic in vitro study of the antibiotic susceptibility of K rhinoscleromatis has been described for two decades, and the efficacies of more lack of effectiveness, since all isolates were inhibited and killed by amoxicillin-clavulanate. We found that tetracycline inhibited most strains that we studied and that chloramphenicol inhibited all strains that we studied, although neither was bactericidal. In contrast, erythromycin inhibited only a few of our strains, although Mazloum (10) found that all strains that he studied were inhibited by 0.25 ,g/ml. Two of our isolates were highly resistant to streptomycin. This may represent mutational resistance, a phenomenon demonstrated with the early use of streptomycin in the treatment of tuberculosis (15) . Despite the in vitro demonstration of susceptibility to sulfonamide, clinical trials in the 1940s did not document the efficacy of this agent (16) . In contrast, more recent studies have shown success with TMP-SMX (1, 9, 18). We found that TMP-SMX inhibited K rhinoscleromatis at low concentrations, although it was relatively less bactericidal than were certain newer agents. Rifampin has been administered by mouth or applied topically for the treatment of rhinoscleroma, with reported success (7, 8, 17) ; the majority of our isolates were not inhibited by c 1 ,ug/ml, which corresponds to readily achievable levels in serum following oral administration, although all isolates were susceptible to four times that concentration. Individual case reports have shown success with ceforanide (3); our data reveal that K rhinoscleromatis is susceptible in vitro to a narrow-spectrum cephalosporin and is highly susceptible to a representative moderate-spectrum cephalosporin and an expanded-spectrum cephalosporin. Although the use of quinolones has not been reported in the treatment of rhinoscleroma, ciprofloxacin appeared to have the greatest activity of any agent that we studied. On the basis of in vitro findings presented here, several antibiotic regimens are likely to be more effective and are certainly more easily administered than streptomycin and tetracycline. Clinical trials that examine the clinical effects of TMP-SMX, ciprofloxacin, and newer cephalosporins appear to be warranted.
Two further features of rhinoscleroma might appear to support the use of ciprofloxacin or rifampin. First, since this disease is generally limited to the tissues of the upper respiratory tract, clinical efficacy may be dependent on the antibiotic levels that can be achieved in nasal secretions. Ciprofloxacin and rifampin both concentrate in these secretory fluids and eradicate susceptible pathogens in the nasopharynx (4). Second, histologic examination of the tissues involved in rhinoscleroma characteristically show large numbers of bacteria within Mikulicz' cells, macrophages that undergo distinctive changes in patients with this disease (19) . This intracellular localization may help to explain the need for prolonged courses of antibiotic treatment and the high rate of relapse following treatment. The well-recognized ability of ciprofloxacin and rifampin to concentrate and kill organisms within macrophages (20) may offer these agents a special advantage in the treatment of rhinoscleroma. Despite these theoretical considerations, the fact that rhinoscleroma is a disease that is largely found in developing countries suggests that attention should be focused on TMP-SMX, a therapy that is likely to be maximally effective at minimal cost. Given the need to administer streptomycin parenterally and the recent difficulty in obtaining this drug, alternative agents must certainly be identified for treatment of rhinoscleroma.
